

Cognitive and Academic Sequele in Bangladeshi Children with Acute Lymphoblastic Leukemia Treated With Long-Term Chemotherapeutic Agents

Md Golam Hafiz^{1,*}, Chowdhury Yakub Jamal²

¹Associate Professor, ²Professor & Chairman, Department of Pediatric Hematology and Oncology, Bangabandhu Sheikh Mujib Medical University, Bangladesh

***Corresponding Author:**

Email: golamhafiz59@yahoo.com

ABSTRACT

The survival rate of childhood acute lymphoblastic leukemia (ALL) is about 90 percent; new research is emerging of its late effects. Literature reviewed investigating the relationship of treatment protocol of ALL too specific late effects, underlying mechanisms and possible remedy.

2,750 diagnosed children of ALL with age of 1-15 years were included in this retrospective study. Literature was surveyed the occurrence and topography of late effects (cognitive and intellectual). The patients had completed the child symptom inventory (CSI) to rate their child's academic performance on a 4-point Likert scale (1=falling, 2=below average, 3=average, 4=above average). Literature was reviewed to find out the underlying mechanisms of these deficits and possible remedy. Here, mice were used as models to answer these questions for assessment of treatment of children with ALL.

Male female ratio was 1.4:1. Based on CSI, 31.81% had below average, 45.27% average and 22.90% above average behavioral and academic performance. Early chemotherapy induced academic and learning deficit was found 34.43%, late 43.48% and no sequelae 22.07%. Early radiation induced cognitive impairment was 23.08% and late 35.52% and had no deficits 41.38%. Neuropsychological impairment was found 24.42% in early phase and 34.9% in late and 40.72% found without any impairment. Chemotherapy induced cognitive impairment at early phase were 38.65%, late 20.39% and 40.94% had no deficits. Male preponderance of these deficits were found both early and late phase of treatment. Childhood leukemia exhibit cognitive and academic deficits and should be placed in a special education program. Behavioral evidence has highlighted impairments in areas of attention, working memory and processing speed leading to decrease in intelligent quotient (IQ). Neurophysiological evidence in ALL has impact abnormalities on white matter and acquired brain damage resulting from chemotherapy.

The exact role of chemotherapeutic agents causing cognitive and academic sequelae is still unknown. The deficits are more pronounced in male at early phase of treatment may be due to increased acceptance of chemotherapeutic agents. Female are affected less may be due to their genetic factors. Cognitive and academic impairment are common following chemotherapy. Radiation also causes cognitive deficits in children with ALL. Neuropsychological impairment was also a feature following chemotherapy in ALL. Improved mice model of cognitive and learning deficits are recommended in survivors of childhood ALL with suggestions for future directions in this field in hopes that ensuing treatment regimens will further reduce or eliminate these deficits in future.

Key words: Cognitive and academic sequelae; Acute lymphoblastic leukemia; Chemotherapeutic agents

Abbreviations: ALL=acute lymphoblastic leukemia; CSI=child symptom inventory; IQ=intelligent quotient

INTRODUCTION

It is evidenced that cancer chemotherapy results in cognitive changes during treatment, immediately post-treatment and years following therapy¹⁻⁶. Cognitive deficits are diverse and vary in severity; however, problems with memory function and executive process are the most common. These impairments can have negative impacts on the quality of life and possess a significant challenge for cancer in children⁷.

Among the survivors of all types of pediatric cancer, the incidence of neuropsychological and neurologic abnormalities is variable, depending on tumors type, location, timing and methods of CNS therapy. The children with brain tumor⁸⁻¹³, acute leukemia¹⁴⁻¹⁹; neuropsychological and neurologic deficits demands special education or even institutionalization in 8%-50%. It is reported that 36 children of various intracranial tumors survived 5 years after treatment,

45% had IQs < 90 and 17% had IQ < 70⁸. The children who had other tumors required specific CNS treatment appear to be at similar risk.

Radiotherapy is the most problematic for growth and development of children with cancer. Learning difficulties among childhood cancer survivors primarily have been attributed to cranial irradiation and are related to their cumulative dose, size of individual fraction and age at time of treatment^{8-11,20-22}. Impairment may be subtle or devastating but normally is not advance after first 3 to 5 years of radiotherapy^{15,21}. The children having brain tumors who are younger than 36 months at diagnosis and those who treated as older brain tumor patients (3,500 to 5,500 cGy) are at increased risk for development serious cognitive impairment and neurologic (blindness and visual impairment)^{9-10,20}.

21 of 28 children who were diagnosed before the age of 36 months were evaluated 8 years after treatment. Significant impairment in neuropsychological and developmental outcome was found in 7 patients who were treated with cranial irradiation (IQ,80) and 14 patients who had received only surgery or chemotherapy (IQ,97)¹¹. Delaying radiotherapy until affected patients are older has been achieved in few patients with good outcome²³⁻²⁴. Lower doses of radiation can be used safely because of antitumor effect of chemotherapy²⁵, neurologic morbidity is expected to be significantly less than before. The earlier results support this prediction²⁶.

CNS directed therapy with cranial irradiation (18 to 24 cGy) which had diminished intelligence IQ, poor academic performance, subsequent development of cancers and endocrinopathies²⁷⁻²⁹. Methotrexate and 5-fluorouracil commonly used cancer chemotherapeutic agents, caused deficits in spatial as well as non-spatial memory. These are consistent with the present findings, and it employed the same drug regimen (once per week for 3 weeks) and recovery period³⁰. Reiriz et al.³¹, reported, cyclophosphamide impaired memory in an inhibitory avoidance task in mice. This is a hippocampal dependent task and involves aversive conditioning. Memory was impaired when a single dose of cyclophosphamide was administered 1 day before but not 1 week before therapy.

Cyclophosphamide or 5-fluorouracil was administered to female rats, which were subsequently tested for spatial learning ability in a Morris water maze task and a T maze active avoidance task³². Rats treated with either drug exhibited enhanced performance. Lee et al. showed, rats were trained 7–9 weeks or 29–42 weeks after chemotherapy which is much later than the 1 week recovery time in relation to our study. Lee et al. showed that different results might be expected when multiple drugs are administered simultaneously rather than individually. Cyclophosphamide and doxorubicin together were administered to most protocol based treatment regimens in various childhood malignancies. The different results may be the age of the patients as well as the female rats in Lee et al.³² were not ovariectomized leading to possible influence and interaction of cycling hormones with chemotherapy. The same chemotherapeutic agents used have been shown to reduce estrogen levels³³ and lower estrogen has been associated with improved performance in spatial tasks³⁴. Different components of the hippocampal system appear to be involved in the spatial tasks reported by Lee et al. and the contextual conditioning procedures used in our study^{35, 36}.

Neurologic hearing loss from therapy with cisplatin³⁷ or aminoglycosides or chronic otitis media, histiocytosis X (Langherhans' cell histiocytosis) and head and neck rhabdomyosarcoma³⁸⁻³⁹. At the extreme end spectrum of chronic neurotoxicity associated with CNS treatment is progressive necrotizing leukoencephalopathy. It is

characterized clinically by dementia, dysarthria, dysphagia, ataxia, spasticity, seizures and coma and histopathologically by reactive astrocytes, gliosis and demyelination⁴⁰.

Following extensive literature search we found no such related publication on cognitive and academic sequelae in Bangladeshi children with ALL treated with long term chemotherapeutic agents. So, to highlight, this retrospective review study was performed to disseminate our observation in perspective of Bangladeshi children.

MATERIALS AND METHODS

This retrospective study was carried out through searching the data in the Department of Pediatric Hematology and Oncology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh from January 2005 to December 2015 in two thousand seven hundred fifty diagnosed children with ALL. Patients were categorized as early phase (≤ 12 month) and late phase (> 12 month) based on the appearance of cognitive and academic sequelae receiving chemotherapy and or radiotherapy.* The clinical performance based measures were with Digital Span Test⁴¹⁻⁴², Verbal Fluency Test⁴³, Grooved Pegboard Test⁴⁴ and Trail Making Test⁴⁵ (DIVERGT). Each patient was administered all measures in a fixed order. All raw scores were converted to age adjusted standard scores on population mean \pm SD (100 ± 15). In addition, caregivers completed the child symptoms inventory (CSI) to rate their child's academic performance on a 4- point Likert scale (1=falling, 2=below average, 3=average, 4=above average). The CSI is a standardized rating scale designed to screen for behavioral, emotional, academic and cognitive symptoms consistent with formal diagnostic criteria⁴⁶. For this study, only the global ratings for academic and cognitive problems were analyzed.

1. Inclusion and Exclusion Criteria

To see the cognitive and academic sequelae treated with chemotherapeutic agents, 1-15 years of diagnosed children with ALL irrespective of gender who received long-term protocol based chemotherapy or radiotherapy were included. The patients with inadequate or poor interventions and any chemotherapy received outside this hospital prior to diagnosis were excluded.

2. Search Strategies

The literature were searched on cognitive and academic sequelae with ALL who were planned to receive protocol based chemotherapy and or radiotherapy using PubMed electronic data base on: 'pediatric cancer,' 'pediatric oncology,' 'hematopoietic stem cell transplantation,' 'bone marrow transplantation,' 'mucositis,' 'stomatitis,' 'chemotherapy,' 'radiotherapy,' and 'acute and long-term effects of chemotherapy,' The abstracts or full texts of original

articles, editorials and communications were also reviewed.

3. Selection of Subjects

Three different observers analyzed the findings of article to locate the potential eligibility of this retrospective study. Articles were selected initially according to the title, then abstracts were reviewed thoroughly and only those articles which were absolutely eligible for this study were selected. Based on the abstracts, full manuscript was acquired for final disposition. In disagreement in between the reviewers, a

fourth reviewer had given power to made final decision on the eligibility of this manuscript.

RESULTS

The flow chart showed search process of articles on cognitive and academic sequelae with acute lymphoblastic leukemia with long term chemotherapy and or radiotherapy (Fig.1). In this review study only 18 articles were finally selected for analysis.





Fig.1: Flowchart of search process on cognitive and academic sequelae with acute lymphoblastic leukemia

The male female ratio of study population was 1.4:1. Mean \pm SD of age 1-5 years, 5-10 years and 10-15 years were 3.5 ± 1.3 , 7.8 ± 2.3 and 11.5 ± 3.6 years respectively (Table 1). The male preponderance of cognitive and academic sequelae was found in all age group of children. The behavioral and academic performance found 31.81% below average, 45.27% average and 22.90% above average based on CSI (Fig. 2). Chemotherapy induced academic and learning deficit had found 34.43% in early phase and 43.48% in late phase of treatment and had no deficit 22.07% with ALL children (Fig. 3). The radiation induced cognitive impairment was 23.08% in early and 35.52% in late phase of therapy but 41.38% had no sequelae (Fig. 4). No neuropsychological impairment found in 40.72% children but had 24.35% in early and 34.9% in late phase of treatment in children with ALL (Fig. 5). Out of 2,750, no chemotherapy induced cognitive impairment found in 40.94% patients but 38.65% in early phase and 20.39% in late phase of treatment (Fig. 6).

Table 1: Age and sex distribution of the children with acute lymphoblastic leukemia (n=2,750)

Age (Year)	Male (%)	Female (%)	Mean \pm SD
1-5	600(21.80)	450(16.36)	3.5 \pm 1.3
5-10	675(24.54)	550(20.00)	7.8 \pm 2.3
10-15	350(12.72)	125(4.54)	11.5 \pm 3.6

**Fig. 2: Child symptom inventory based behavioral and academic performance (n=2,750)**

DISCUSSION

1. Late Effects of Childhood Cancer

Out of 10 million cancer survivors alive in United States today, at least 270,000 patients were diagnosed when they were under the age of 21⁴⁷, though there are no national wide definite registration of cancer patients in our country, the value is definitely less, it is about 12,000 because of poor diagnostic facilities. With the advancement of cancer treatment over the past few decades, new research focuses on ‘late effects’, chronic and progressive conditions associated with completion of cancer therapy, now prevalent among long-term cancer survivors. It usually present three or more years of diagnosis with only one in three survivors free of long-term effects^{48,49}. Late effects among cancer survivors are so pervasive that the Children’s Oncology Group (COG) has recommended regular evaluation to monitor the development after treatment which is difficult to follow-up due to time constrain and expensive assessments⁵⁰.

Cognitive late effects presumably resulting from chemotherapy administered to the central nervous system (CNS) during the time of rapid brain development^{49,51}. Childhood cancer survivors compared to their counterpart are 10 times more likely to have severe cognitive deficits and significantly less likely to complete high school or to complete higher education after graduation^{49,52}. Frequency of impairment of task efficiency, memory and emotional regulation is 50% higher among adulthood survivor of childhood cancer compared to siblings⁵³. In this review study behavioral

and academic performance found 31.81% below average, 45.27% average and 22.90% above average based on CSI scale (Fig. 2).

ALL is the most common disease among childhood cancer survivors⁵⁴. With advanced treatment regimen, more 90% of children with ALL enter into long-term remission with highest survival rate⁵⁴. Literature review on cognitive late effects associated with treatment ALL exist⁵⁵⁻⁵⁶, whereas evaluation of cognitive late effects in preclinical models of young mice is still lacking. Objective of this current review is to highlight the benefits of using preclinical models to complement the research.

2. Acute Lymphoblastic Leukemia (ALL)

Leukemia represents about one-third of all childhood cancers, ALL accounting for 75% of pediatric leukemia, the most common form of cancer in children and adolescents⁵⁷. Out of 4,000 cases diagnosed annually in the United States, two-thirds are in these age groups [58]. In our perspective, about 1,500 newly diagnosed ALL are admitted annually in our hospital. It is the malignant disorder of lymphoid cells when a surplus of stem cells develops into lymphocytes referred to as leukemic cells which are not able to fight against infection and leave less room for healthy cells and platelets⁵⁸. These cells are found in bone marrow are transferred by the circulatory system including CNS. Despite possible environmental, genetic and viral influences the exact cause of ALL remains unknown⁵⁹. While ALL is less prevalent in adults, mortality rate

among them is much higher than in adolescents and children. Treatment for the majority of ALL subtypes consists of four phases: induction, intensification (consolidation), high dose or CNS directed therapy and maintenance. Although two-thirds of childhood cases are curable with only 12 months of treatment, the vast majority of patients undergo therapy for two years or more [58]. In our center we treat the child more or less 36 month depending on the risk group. Chemotherapeutic agents used vary in type and doses, most common being used are methotrexate (MTX), cytosine arabinoside (cytarabine), anthracyclines (doxorubicin), asparaginase, mercaptopurine, vincristine, and corticosteroids⁵⁸. Cranial irradiation therapy (CRT), once the most common form of CNS prophylaxis has largely been replaced by intrathecal (IT) and systemic chemotherapy. This change has been made to eliminate radiation induced CNS damage⁶⁰. The alterations in long-term outcome are just beginning to unfold⁶¹.

3. Academic and Learning Deficits

Childhood ALL and its treatment are associated with poor academic outcome with age at diagnosis is

important education related risk factor. Infantile leukemia found to have 50% learning deficits more than five years after diagnosis and risk increased with younger age at the time of therapy⁶². Survivors of ALL have likelihood of being placed in a special education program and reach a lower educational level than their siblings⁶³⁻⁶⁴. ALL treatment during childhood is related to poor academic performance, clear learning deficits may not arise until four or five years after the initiation of therapy⁶⁵. Poor academic performance is not correlated with frequent absent from school⁶⁶. Past treatment for ALL commonly included CRT; the majority of studies on this topic have included radiation as part of treatment, but rarely without simultaneous use of chemotherapy⁴⁸. General measures of intellectual functioning were used Wechsler Intelligence Scales⁶⁷. The scores declined seven years following treatment with cranial irradiation⁶⁸. The childhood cancer survivors display a decreased rate of learning new information and new skills, leading to a decline in IQ score^{48,69}. Here, early chemotherapy induced academic and learning deficit was 34.43%, late 43.48% and no sequelae 22.07% of childhood cancer survivors (Fig. 3).




Fig. 3: Chemotherapy induced academic and learning deficit

Comparisons between CNS prophylaxes involving CRT or IT have yielded mixed results with no significant difference between the group. 12-point difference in mean IQ was found between ALL and controls irrespective of CNS prophylaxis⁷⁰. The radiation and non-radiation groups demonstrated deficits may indicate synergistic effects between MTX and cytarabine, the latter increasing the neurotoxic effects of the former, the result are similar to CRT. No significant influence of treatment was found between children who received IT-MTX in addition to systemic MTX, a lower dose of CRT or a higher dose of CRT, although 22 to 30 percent of children found a significant decline in IQ [69]. In this review study radiation induced cognitive impairment was 23.08% in early and 35.52% in late phase of therapy but 41.38% had no sequelae (Fig. 4). Systemic MTX may potentiate the neurotoxic effects of IT-MTX affecting brain via indirect pathways⁷¹. High doses of IV-MTX may reduce vascularization of the brain, particularly hippocampal blood vessel density⁷².

Loss of intellectual functioning is characterized by deficits in attention, working memory and processing speed⁵⁹. Neurocognitive impairments in ALL survivors have focused on deficits in attention (approx. 25%) of survivors⁷³.

Deficits in the targeting, recalling and manipulating of information to guide goal-directed behavior have been noted seven years post-treatment⁷⁴⁻⁷⁵. ALL survivors found to have performance on visual attention which required the child to shift attention between the local and global level of stimuli⁷⁶. Children diagnosed younger than 5 years exhibit difficulties in both fundamental and complex attention skills. Children diagnosed more than 5 years have difficulty with more complex skills only⁷⁷. Deficits in more complex skills arise from reduced fluency. Age at diagnosis may impact attention functioning in children with intensified treatments results more extensive and widespread deficits⁷⁸.

Disruption in basic skills may not become apparent until difficulties with higher level several years later, when emergences of complex repertoires from component skills not found in normal progression. ALL survivors decrease in IQ level in cognitive skills of processing speed, working memory and intelligence with processing speed playing a significant role in the development of working memory⁷⁹. Working memory underlies the development of higher-level reasoning and intelligence. Evidence for impaired working memory and slowed information processing has been found for ALL survivors received chemotherapy⁸⁰⁻⁸³.




Fig. 4: Radiation induced cognitive impairment

The substitution of IT for cranial irradiation has possibly reduced the severity of the impairments outlined above⁷⁸⁻⁷⁹, but evidence of long-term neurocognitive deficits in ALL still exists^{55-56,82}. As compared to newly diagnosed children who had completed 3 years treatment had greater cognitive impairments and to have learning disabilities despite the fact that no learning difficulties had been found in these children prior to chemotherapy⁶⁵. Triple IT therapy (MTX, cytarabine and hydrocortisone), no significant difference in the level of cognitive impairment was found between the groups, although the MTX group showed a slightly slower processing speed⁸⁶. About 40 percent of childhood cancer survivors given chemotherapy may experience neurocognitive deficits years' later⁵⁰.

The impacts of chemotherapy for ALL are inconsistent possibly because of differences among methodological approaches and protocols. There are multiple methodological challenges in longitudinal cognitive

assessment, such as selection of appropriate neurocognitive domains and control groups, differences in criteria for impairment and repeated testing⁸⁷. The percentage of ALL survivors experiencing neurocognitive deficits may be raised up to 70 percent depending on the specific type of cognitive domain assessed in working memory⁸⁸. ALL treatment protocols often vary leaving the question of which agents and doses affect neurocognitive outcome still uncertain⁵⁶⁻⁵⁷. Treatment is comprised of multiple phases with a unique combination of drugs even a single agent substitution within the complex protocol alters whether or not cognitive late effects appear⁸⁹.

4. Neurophysiological Evidence

Neurophysiological deficits are common among childhood ALL survivors have implicated white matter abnormalities results from a disruption of myelination process during childhood⁴⁸. Along with white matter hypodensity, MTX causes leukoencephalopathy,

multiple necrotic lesions in the periventricular white matter^{59,90}. Behavioral symptoms develop gradually over a period of time with reduced attentiveness and intellectual deficits⁹¹. Impairment in attention accounted for a significant amount relating to decreased volumes of normal white matter and IQ⁹². The cumulative dose of IT- MTX (12 to 30) correlates positively with deficits in neuropsychological, attention and concentration⁹³. Following MTX therapy identification of folate pathway in genetic polymorphisms predicts childhood cancer patients developing impairment in attention⁷³. Myelination causes the functional maturation across brain regions⁹⁴. During early childhood frontal lobe undergoes a significant amount of myelination⁴⁸. Myelination in this area typically occurs later in the development and mature frontal lobe characteristically has high volume of white matter, so, it is more

vulnerable to damage early in brain development. The reduction in volume of dorsolateral prefrontal cortices, mammillary bodies and caudate nuclei in survivors who had received three years IT chemotherapy⁹⁵. It is observed that no neuropsychological impairment found in 40.72% children but had 24.35% in early and 34.9% in late phase of treatment in children with ALL survivors (Fig. 5). No significant difference in volumetric brain size, but a reduction was found in both the mammillary bodies and dorsolateral prefrontal cortices. This pattern of abnormality corresponds to deficits of memory, processing speed, distractibility and attention. Advanced neuroimaging techniques that allow for more precise measurement of myelin integrity and degradation, which include diffusion tensor imaging, quantitative magnetization transfer imaging and quantitative multiple exponential T2 measurements⁸⁸.




Fig. 5: Chemotherapy induced neuropsychological impairment

Primary, non-cancer cells are more vulnerable to the toxic effects of cytarabine, BCNU and cisplatin than cancer cells. At low-dose 60% oligodendrocytes are killed within 24 hours. Similarly, equivalent to the lower end of high-dose, nearly all oligodendrocytes are killed along with 50% glial-restricted precursor cells⁹⁶. Once it is thought that a chemotherapeutic agent (doxorubicin) is unable to cross the blood-brain barrier reduces neural cell proliferation in dentate gyrus⁹⁷. This is not evaluated from a developmental standpoint which is important to consider since blood-brain barrier of child is still undergoing development and is more susceptible to chemotherapy induced CNS damage.

Potential mechanisms of underlying chemotherapy induced cognitive deficits have been proposed specifically in relation to childhood cancer survivors. White matter damage and reduced cell proliferation may be increased oxidative stress, neuroinflammation, reduced blood flow, deregulation of the immune response and deficits in DNA-repair⁹⁸⁻⁹⁹. The effects of chemotherapeutic agents using neural cells, immature brains and mature brains may provide valuable insight into the mechanisms of cognitive late effects in ALL cancer survivors. In this review study, out of 2,750, no chemotherapy induced cognitive impairment found in 40.94% patients but 38.65% in early phase and 20.39% in late phase of treatment of childhood cancer survivors (Fig. 6).




Fig. 6: Chemotherapy induced cognitive impairment

5. Benefits of Preclinical Mice Models

It is not possible to conduct a research in a patient which is needed to answer the interrelated questions which drugs combination or doses are at risk. Assessment of cognitive outcome would take longer time for cure of the children¹⁰⁰. It is difficult to distinguish drug effects from other factors (physiological consequences or patient depression)¹⁰¹. The use of preclinical models is another way to find the deficits of learning processes by chemotherapy. This allows drug effects independently of other contributing factors and provides a rapid way to evaluate many drugs. Chemotherapeutic agents and mice models have involved drug application of a single agent¹⁰²⁻¹⁰⁴, but mice model make it possible to study drug combinations. Mechanisms of chemotherapy induced neurotoxicity can be studied using preclinical models. Methylphenidate is used to treatment cognitive late effects in childhood cancer survivors¹⁰⁵⁻¹⁰⁷. Sex differences among drug effects can be studied in mice; it is reported that girls are more susceptible to the neurotoxic effects of these agents¹⁰⁸. But in this study, male preponderance of these deficits were found both early and late phase of treatment (Fig. 3-6).

Mechanisms for chemotherapy induced neurotoxicity in clinical studies are little known, preclinical models in mice have reported that MTX and cytarabine cross blood-brain barrier in various routes. Cell death and disruption of cell division occurs *in vivo* after giving three i.v. dose of cytarabine in mice⁹⁶. A single i.v. MTX (37.5-300 mg/kg) reduces hippocampal cell proliferation. The hippocampus is important for learning and memory; detrimental effects on cognitive performance results if neurogenesis is disturbed¹⁰⁹.

Intraventricular injections of MTX in mice for three alternative days resulted in lowered concentrations of hippocampal brain amines. These findings are consistent in which adult mice treated with MTX failed to learn to avoid an aversive stimulus relative to controls¹¹⁰. MTX (0.05 mg/kg or 0.1 mg/kg, i.p) administered during brain development in mice results in reduced density of synapses of the hippocampus¹¹¹. Five repeated doses of intraventricular injection of MTX (1-2 mg/kg) produced neuropathological changes similar to the damage seen in human patients¹¹². In this review study, it is found that the patients were given three high dose of MTX (2.5gm/m²) during CNS directed therapy. So, there is definitely a detrimental effect on cognitive performance, which is consistent with the observation of authors.

Preclinical models have been useful to investigate chemotherapy induced deficits in learning and memory using adult models of breast cancer treatment of behavioral assays¹¹³⁻¹¹⁶. Mice have highlighted the possibility of drug combinations that have a greater effect than either drug alone. Chemotherapy induced cognitive deficits have been examined in mice with anti-depressants to block decreased cell proliferation treated with 5-fluorouracil¹¹⁷. Fluoxetine reverses depression of neurogenesis caused by MTX in mice¹¹⁸. These will guide the physicians about treatment options that decrease chemotherapy induced cognitive deficits and if require to treat these form of deficits in children with ALL¹¹⁵. Though Fluoxetine not yet started in our setting, very soon it will be added in ALL patients following high dose MTX therapy to prevent these unwanted deficits in future.

6. Mice Models of Childhood Cancer Treatment

Neonatal damage has been found to have more severe long-term deficits than damage in mature adult brain [119]. The first assessment of cancer treatment on developing brains used young rat pups at PND 17, an age selected because of developmental similarities to newborn infants. Treatment included CRT alone (1,000 R), MTX alone (5mg/kg, i.p), or a combination of CRT and MTX. Testing with a simultaneous discrimination task began when the rats were 12-14 weeks old. It is observed that mice receiving a combination therapy were significantly slower development compared to others¹⁰³.

Treatment protocols of ALL that include multiple phases of therapy of two years with single dose of radiation and /or MTX. This was done because of rats at this age develops at an exceedingly faster rate. This limitation is shared among the majority of studies using mice models to investigate childhood cancer treatment in young pups. 16-17 days old rat pups were treated with a single dose of MTX (0.005 mg/kg, i.p). At 12-14 weeks, they were tested on conditioned response and conditioned taste aversion tasks. Those treated with MTX developed delay conditioning at a slower rate. MTX-treated animals failed to display a taste aversion compared to controls, but were equal to controls by the next trial. Neonatal mice received MTX were slower to learn about environmental events [104] but no impairments were found in 17 day rat treated with MTX (0.005 mg/kg, i.p.). In contrast, no impairment was found on a more complex Pavlovian conditioning task focusing on negative discrimination¹⁰².

Childhood cancer therapy consists of different drugs which was studied in mice with nine different treatment combinations of MTX (2 or 4 mg/kg, i.p.), prednisolone (18 or 36 mg/kg,i.p) and CRT (1000 cGy), treated at PND 17-18 [120]. Prednisolones are commonly included among the drugs used in ALL (double and triple IT) therapy and it is reported that glucocorticoid potentiate hippocampal damage by neurotoxins¹²¹. We had observed greater behavioral deficits in treatment group. Females showed altered behavior at lower doses than males¹²⁰. The girls may be more susceptible to untoward effects of these drugs¹⁰⁸ but we found it more in male. While prednisolone antagonized MTX thereby, preventing behavioral alterations at low doses; it enhanced MTX and CRT related deficits at high doses¹²⁰.

Multidrug chemotherapeutic agents are used in ALL, but knowledge pertaining to individual agents to neurocognitive deficits is little known. The potential deficits of cytarabine, vincristine, doxorubicin and L-asparaginase cannot be dismissed to neurocognitive deficits. Preclinical models have provided evidence of cognitive disruption following administration of such agents. Cytarabine produced impairment in long-term spatial memory in mice after 30 days but not in the first day¹²². Vincristine causes disruption of sensory

processing (neuropathies and mechanical sensitivity)¹²³, but impairment measured by the Morris water maze has found at high doses¹²⁴. Only doxorubicin therapy led to impairment in inhibitory avoidance conditioning in mice but not on a passive avoidance task¹²⁵⁻¹²⁶. Combination therapy with cyclophosphamide and doxorubicin produced impairment in contextual fear conditioning and passive avoidance learning¹²⁷⁻¹²⁸. The correlation between L-asparaginase and cognition has not yet been observed, an important factor to consider for future research. The effects of corticosteroids commonly used in combination therapy are correlated with poor cognitive outcome. The children treated with dexamethasone may be at greater risk of late neurocognitive effects compared to children of ALL treated with prednisone⁸⁹.

CONCLUSION

The exact role of chemotherapeutic agents causing cognitive and academic sequelae is still under debate. The deficits are more pronounced in male at early phase of treatment may be due to increased acceptance of chemotherapeutic agents. Female are affected less may be due to their genetic factors. Cognitive and academic impairment are common following chemotherapy. Radiation also causes cognitive deficits in children with ALL. Neuropsychological impairment was also a feature following chemotherapy in ALL.

The survival rate for childhood cancer is gradually increasing; new researches are required what happens after remission. It is necessary for children and their parents to know the potential late effects of therapy⁴⁷. They should be followed up for several years after treatment for emerging medical complications and academic problems. Further guidelines for childhood cancer survivors are outlined⁴⁷. Assessment tools that can quickly identify the risk survivors are now under development¹²⁹. Judgment of multimodal treatment protocols is necessary to evaluate specific drug effects that can lead to cognitive late effects. These will help the physicians about treatment options that reduce or eliminate chemotherapy induced neurocognitive deficits which have been supported by behavioral and neurophysiological evidence.

FURTHER SUGGESTION

Development of blood-brain barrier and lack of certain enzymes at early stages will impact how chemotherapeutic agents are metabolized by the body, as well as how the brain is affected. Dosage and route of administration also take these developmental aspects. This needs to be taken into consideration when choosing behavioral assays. Building a bridge between clinical and preclinical research would greatly improve the study of chemotherapy induced cognitive effects of childhood cancer treatment. Future preclinical research in this area should aim to provide a more accurate model of clinical treatment through alterations in drug

selection, treatment regimen and behavioral aspects. Since MTX and cytarabine are commonly administered during CNS prophylaxis, it would be valuable to investigate the effects of this specific combination of chemotherapeutic agents. Preclinical models are ideal for parsing apart the individual and combined effects on learning and memory where chemotherapeutic agents are used. Repeated administration of these agents can be examined by treating pre weanling pups on multiple consecutive days early in development rather than a single administration. Mice can be assessed during adolescence (PND 35) and adulthood (PND 60) for long-term effects of neurotoxicity. Appropriate behavioral assays need to be selected for neurocognitive deficits in ALL survivors. Since the exact mechanisms of chemotherapy induced cognitive impairment are not yet fully understood, a battery of preclinical assays of learning and memory should be studied, as sensitivity to chemotherapy induced cognitive deficits differs among tasks in models of adult chemotherapeutic treatment⁹⁹.

ACKNOWLEDGEMENT

I express my sincere thanks to the staffs of the Department of Pediatric Hematology and Oncology, BSMMU, for their cordial helps regarding the preparation of investigations for this research.

CONFLICTS OF INTEREST

The author declares no conflicts of interest regarding the publication of this paper.

ETHICAL CONSIDERATION

The Institutional ethical committee and review board of BSMMU approved the protocols and signed informed consent was obtained from the patients, their parents or their guardians as appropriate.

LIMITATIONS OF THE STUDY

This was mostly based on single center which resulted in the limitations for conclusive message, demanding the need for further multicenter study with large sample size on chemotherapy induced cognitive impairment in children with acute lymphoblastic leukemia.

DISCLOSURE

This paper has been read and approved by the author, has not been published totally or partly in any other journal and will not be published in any other periodicals.

FUNDING OF THE STUDY

No funding had been taken from the department or from the parents.

AUTHOR CONTRIBUTION

This work was carried out in collaboration between the authors. Author MGH designed the study, wrote the

protocol and interpreted the data. He also managed the literature searches and produced the initial draft. Author CYJ anchored the field study, gathered initial data and performed preliminary data analysis. He also managed the literature searches. Both the authors read and approved the final manuscript.

REFERENCES

- Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Sakalla K, et al. Neuropsychological impact of standard-dose chemotherapy in long-term survivors of breast cancer and lymphoma. *J Clin Oncol*. 2002; 20: 485–93. [PubMed: 11786578]
- Brezden C, Philips K, Abdolell M. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. *J Clin Oncol*. 2000; 18:2695–701. [PubMed: 10894868]
- Jansen C, Miaskowski C, Dodd M, Dowling G, Kramer J. Potential mechanisms for chemotherapy induced impairments in cognitive function. *Oncol Nurs Forum*. 2005; 32:1151–63. [PubMed: 16270111]
- Mc Allister TW, Ahles TA, Saykin AJ, Ferguson RJ, McDonald BC, Lewis LD, et al. Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments. *Curr Psychiatry Rep*. 2004; 6:364–71. [PubMed: 15355759]
- Saykin AJ, Ahles TA, McDonald BC. Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological and neuroimaging perspectives. *Semin Clin Neuropsychiatry*. 2003; 8:201–216. [PubMed: 14613048]
- Van Dam F, Schagen S, Muller M. Impairment of cognitive function in women receiving adjuvant treatment for high risk breast cancer: high dose versus standard dose chemotherapy. *J Natl Cancer Inst*. 1998; 90:210–8. [PubMed: 9462678]
- Ferrell B, Hassey-Dow K. Quality of life among long-term cancer survivors. *Oncology*. 1997; 11:565–76. [PubMed: 9130276]
- Danoff BF, Cowcho9ck FS, Marquette C, Mulgrew L, Kramer S. Assessment of the long-term effects of primary radiation therapy for brain tumors in children. *Cancer*. 1982; 49:1580.
- Cohen BH, Packer RJ, Siegel KR, et al. Brain tumors in children under 2 years: treatment, survival and long-term prognosis. *Pediatr Neurosurg* 1993; 19:171-179.
- Dennis M, Spiegler BJ, Hetherington CR, et al. Neuropsychological sequelae of the treatment of children with medulloblastoma. *J Neuro Oncol* 1996; 29:91.
- Copeland DR, de Moor C, moor BD, Ater JL. Neurocognitive development of children after a cerebellar tumor in infancy: a longitudinal study. *J Clin Oncol* 1999; 17:3476.
- Packer RJ, Meados AT, Rorke MLB, et al. Long term sequelae of cancer treatment on the central nervous system in childhood. *Med Pediatr Oncol* 1987; 15:241.
- Ellenberg L, McComb JG, Siegel SE, Stowe S. Factors affecting intellectual outcome in pediatric brain tumors patients. *Neurosurgery* 1987; 21:638.
- Mulhern RK, Fair clough D, Ochs J. A prospective comparison of neuropsychologic performance of children surviving leukemia who receive 18 Gy, or no cranial irradiation. *J Clin Oncol* 1991; 9:1348.
- Moore IM, Kramer JH, Wara W, et al. Cognitive function in children with leukemia: effect of radiation dose and time since radiation. *Cancer* 1999; 68:1913.

16. Rubenstein CI, Varni JW, Karz ER. Cognitive functioning in long-term survivors of childhood leukemia: a prospective analysis. *J Develop Behav Pediatr* 1990; 11:301.
17. Fletcher JM, Copeland DR. Neurobehavioral effects of central nervous system prophylaxis treatment of cancer in children. *J Clin Exp Neuropsychol* 1988; 10:495.
18. Christie D, Leiper AD, Chessells JM, et al. Intellectual performance after presymptomatic cranial radiotherapy for leukemia: effect of age and sex. *Arch Dis Child* 1995; 73:136.
19. Maclean WF, Noll RB, Stehbins JA, et al. Neuropsychological effects of cranial irradiation in young children with acute lymphoblastic leukemia 9 months after diagnosis *Arch Neur* 1995;52:156.
20. Walter AW, Mulhern RK, Gajjar A, et al. Survival and neurodevelopmental outcome of young children with medulloblastoma at St. Jude's Children Research Hospital. *J Clin Oncol* 1999; 17:372.
21. Kun LE, Mulhern RK. Neuropsychologic function in children with brain tumors. Serial studies of intellect and time after treatment. *Am J Clin Oncol* 1983; 6:651.
22. Packer RJ, Meadows AT, Rorke MLB, et al. long term sequelae of cancer treatment on the central nervous system in childhood. *Med Pediatr Oncol* 1987; 15:241.
23. Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. *N Eng J Med* 1993; 328:1725.
24. Ater JL, van Eys J, Woo SY, et al. MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children. *J Neuro Oncol* 1997; 32:243-252.
25. Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A children Cancer Group Study. *J Clin Oncol* 1999; 17:2127-2136.
26. Goldwein JW, Radcliffe J, Johnson J, et al. Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). *Int Radiat Oncol Biol Phys* 1996; 34:899-904.
27. Cousens P, Waters B, Said J, et al. Cognitive effects of cranial irradiation on leukemia: A survey and meta-analysis. *J Child Psychol Psychiatry* 1988; 29:839-852.
28. Meadows AT, Gordon J, Massari DJ, et al. Declines in IQ score and cognitive dysfunctions in children with acute lymphoblastic leukemia treated with cranial irradiation. *1981; 2:1515-1518.*
29. Oberfield SE, Nirenberg A, Allen JC, et al. Hypothalamic pituitary-adrenal function following cranial irradiation. *Home Research* 1997; 47:9-16.
30. Winocur G, Vardy J, Binns MA, Kerr L, Tannock I. The effects of anti-cancer drugs, methotrexate and 5-fluorouracil on cognitive function in mice. *Pharm Biochem Behav.* 2006; 85:66-75.
31. Reiriz AB, Reolon GK, Preissler T, Rosado JO, Henriques JA, Roesler R, et al. Cancer chemotherapy and cognitive function in rodent models: memory impairment induced by cyclophosphamide in mice. *Clin Cancer Res.* 2006; 12:5000. [PubMed: 16914590]
32. Lee GD, Longo DL, Wang Y, Rifkind JM, Abdul-Raman L, Mamczarz JA, et al. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. *Clin Cancer Res.* 2006; 12:198-205. [PubMed: 16397043]
33. Jarrell J, Lai EV, Barr R, McMahon A, Belbeck L, O'Connell G. Ovarian toxicity of cyclophosphamide alone and in combination with ovarian irradiation in the rat. *Cancer Res.* 1987; 47:2340-3. [PubMed: 3105875]
34. Galea LA, Kavaliers M, Ossenkopp KP, Hampson E. Gonadal hormone levels and spatial learning performance in the Morris water maze in male and female meadow voles, *Microtus pennsylvanicus*. *Horm Behav.* 1995; 29:106-25. [PubMed: 7782059]
35. Burwell RD, Saddoris MP, Bucci DJ, Wiig KA. Corticohippocampal contributions to spatial and contextual learning. *J Neurosci.* 2004; 24:3826-36. [PubMed: 15084664]
36. Good M, Honey RC. Dissociable effects of selective lesions to hippocampal subsystems on exploratory behavior, contextual learning, and spatial learning. *Behav Neurosci.* 1997; 111:487-93. [PubMed: 9189263]
37. Schell MJ, Mc Haney VA, Green AA, et al. hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. *J Clin Oncol* 1989; 7:754.
38. Saman NA, Vieto R, Schultz PN. Hypothalamic, pituitary and thyroid function after radiotherapy to the head and neck. *Int J Radiat Oncol Biol* 1982; 8:1857.
39. Tefft M, Lattin PB, Jereb B, et al. Acute and late effects on normal tissue following combined chemo and radiotherapy for childhood rhabdomyosarcoma and Ewing's sarcoma. *Cancer* 1976; 37:1201.
40. Pizzo P, Poplack DG, Bleyer WA. Neurotoxicities of current leukemia therapy. *Am J Pediatr Hematol Oncol* 1979; 1:27.
41. Wechsler D. Wechsler Intelligence Scale for Children (ed 3). San Antonio, TX, Psychological Corporation, 1991.
42. Wechsler D. Wechsler Adult Intelligence Scale (ed 3). San Antonio, TX, Psychological Corporation, 1997.
43. Benton AL, Hamsher K, Sivan AB. Multilingual Aphasi Examination (ed 3). Iowa City, IA, AJA Associates, 1983.
44. Trites RL. Neuropsychological Test Manual. Ottawa, Ontario, Canada, Royal Ottawa Hospital, 1977.
45. Reitan R. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation (ed2). Tucson, AZ, Neuropsychology Press, 1993.
46. Gadow KD, Sprafkin J. Child Symptom Inventory. Stony Brook, NY Checkmate Plus, Ltd, 1997.
47. Children Oncology Group. Establishing and enhancing services for childhood cancer survivors: long-term follow-up program resource guide. [http://www.survivorshipguidelines.org/\[internate\]](http://www.survivorshipguidelines.org/[internate])
48. Moleski M. Neuropsychological, neuroanatomical and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. *Arch Clin Neuropsych* 2000; 15:603-630.
49. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. *N Eng J Med* 2006; 355:1572-1582.
50. Krull KR, Okcu MF, Potter B, et al. Screening for neurocognitive impairment in pediatric cancer long-term survivors. *J Clin Oncol* 2008; 26:4138-4143.
51. Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the childhood cancer survivor study. *J Clin Oncol* 2006;24:5277-5282.
52. Mulrooney DA, Dover DC, Li S, et al. Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia. *Cancer* 2008; 112:2071-2079.
53. Kadan-Lottick NS, Zeltzer LK, Liu Q, et al. Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. *J Nat Canc Inst* 2010; 102:881-893.
54. Pui C and Evans WE. Treatment of acute lymphoblastic leukemia. *N Engl J Med* 2006; 354:166-178.

55. Buizer AL, de Sonneville LMJ and Veerman AJP. Effects of chemotherapy on neurocognitive function in children with acute lymphoblastic leukemia: a critical review of the literature. *Pediatr Blood and Cancer* 2009; 52:447-454.
56. Janzen LA and Spiegler BJ. Neurodevelopmental sequelae of pediatric acute lymphoblastic leukemia and its treatment. *Dev Dis Rev* 2008; 14:185-195.
57. Butler RW and Haser JK. Neurocognitive effects of treatment for childhood cancer. *Ment Retard Dev Dis Rev* 2006; 12:184-191.
58. Pui C and Evans WE. Treatment of acute lymphoblastic leukemia. *N Engl J Med* 2006; 354: 166-178.
59. Mulhern RK and Butler RW. Neurocognitive sequelae of childhood cancers and their treatment. *Pediatr Rehabilitation* 2004; 7: 1-14.
60. Stehbens JA, Kaleita TA, Noll RB, et al. CNS prophylaxis of childhood leukemia: what are the long-term neurological, neuropsychological, and behavioral effects? *Neuropsychol Rev*. 1991; 2: 147-177.
61. Pui C, Campana D, Pei D, et al. Treatment of childhood acute lymphoblastic leukemia without prophylactic cranial irradiation. *N Engl J Med* 2009; 360:2730-2741.
62. Leung W, Hudson M, Zhu Y, et al. Late effects of survivors of infant leukemia. *Leukemia* 2000; 14:1185-1190.
63. Haupt R, Fears TR, Robinson LL, et al. Educational attainment in long-term survivors of childhood acute lymphoblastic leukemia. *JAMA*1994; 272: 1427-1432.
64. Kingma A, Rammeloo LAJ, van der Does-van den Berg A, et al. Academic career after treatment for acute lymphoblastic leukaemia. *Arch Dis Child* 2000; 82:353-357.
65. Brown RT, Madan-Swain A, Pais R, et al. Chemotherapy for acute lymphocytic leukemia: cognitive and academic sequelae. *J Pediatr* 1992; 121: 885-889.
66. Taylor, HG, Albo VC, Phebus C, et al. Post irradiation treatment outcomes for children with acute lymphocytic leukemia. *J Pediatr Psychol* 1987; 12: 394-411.
67. Moss HA, Nannis ED and Poplack DG. The effects of prophylactic treatment of the central nervous system on the intellectual functioning of children with acute lymphocytic leukemia. *Am J Med* 1981; 71: 47-52.
68. Jankovic M, Brouwers P, Valsecchi MG, et al. Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia. *Lancet*.1994; 344:224-227.
69. Mulhern RK, Fairclough D and Ochs J. A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation. *J Clin Oncol*. 1991; 9:1348-1356.
70. Giralt J, Ortega JJ, Olive T, et al. Long-term neuropsychologic sequelae of childhood leukemia: comparison of two CNS prophylactic regimens. *Int J Radiat Oncol*1992; 24: 49-53.
71. Espy KA, Moore IM, Kaufmann PM, et al. Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lymphoblastic leukemia: a prospective study. *J Pediatr Psychol* 2001; 26:1-9.
72. Seigers R, Timmermans J, van der Horn HJ, et al. Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release. *Behav Brain Res* 2010; 207: 265-272.
73. Krull KR, Brouwers P, Neelam J, et al. Pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors. *J Pediatr* 2008; 152:101-105.
74. Rodgers J, Horrocks J, Britton PG, et al. Attentional ability among survivors of leukaemia. *Arch Dis Child* 1999; 80: 318-323.
75. Langer T, Martus P, Ottensmeier H, et al. CNS late-effects after ALL therapy in childhood. Part III: Neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory. *Med Pediatr Oncol* 2002; 38: 320-328.
76. Schatz J, Kramer JH, Ablin AR, et al. Visual attention in long-term survivors of leukemia receiving cranial radiation therapy. *J Int Neuropsychol Soc* 2004; 10: 211-220.
77. Lockwood KA, Bell TS and Colegrove RW. Long-term effects of cranial radiation therapy on attentional functioning in survivors of childhood leukemia. *J Pediatr Psychol*1999; 24:55-66.
78. Buizer AI, de Sonneville LMJ, van den Heuvel-Eibrink MM, et al. Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer* 2005; 45: 281-290.
79. Schatz J, Kramer JH, Ablin A, et al. Processing speed, working memory, and IQ: a developmental model of cognitive deficits following cranial radiation therapy. *Neuropsychology* 2000; 14:189-200.
80. Ashford J, Schoffstall C, Reddick WE, et al. Attention and working memory abilities in children treated for acute lymphoblastic leukemia. *Cancer* 2010; 116: 4638-4645.
81. Mennes M, Stiers P, Vandenbussche E, et al. Attention and information processing in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. *Pediatr Blood Cancer* 2005; 44: 479-486.
82. Campbell LK, Scaduto M, Sharp W, et al. A meta-analysis of the neurocognitive sequelae of treatment for childhood acute lymphocytic leukemia. *Pediatr Blood Cancer* 2007; 49: 65-73.
83. Jain N, Brouwers P, Okcu M, et al. Sex-specific attention problems in long-term survivors of pediatric acute lymphoblastic leukemia. *Cancer* 2009; 115: 4238-4245.
84. Spiegler BJ, Kennedy K, Maze R, et al. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. *J Clin Oncol* 2006; 24: 3858-3864.
85. Waber DP, Turek J, Catania L, et al. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiations as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber cancer institute ALL consortium protocol 95-01. *J Clin Oncol*2007; 25: 4914-4921.
86. Kadan-Lottick NS, Brouwers P, Breiger D, et al. Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia. *J Clin Oncol* 2009; 27: 5986-5992.
87. Vardy J, Wefel JS, Ahles T, et al. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the venice cognitive workshop. *Ann Oncol* 2008; 19: 623-629.
88. Reddick WE, & Conklin HM. Impact of acute lymphoblastic leukemia therapy on attention and working memory in children. *Expert Rev Hematol* 2010; 3: 655-659.
89. Waber DP, Carpentieri SC, Klar N, et al. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. *J Pediatr Hematol Oncol* 2000; 22: 206-213.
90. Ochs, JJ. Neurotoxicity due to central nervous system therapy for childhood leukemia. *Am J Pediatr Hematol Oncol* 1989; 11:93-105.
91. Lee YY, Nauert C, & Glass P. Treatment-related white matter changes in cancer patients. *Cancer* 1986; 57: 1473-1482.
92. Reddick WE, White HA, Glass JO, et al. Developmental model relating white matter volume to neurocognitive

- deficits in pediatric brain tumor survivors. *Cancer* 2003; 97:2512-2519.
93. Steinberg S, Hartmann R, Wisniewski S, et al. Late sequelae of CNS recurrence of acute lymphoblastic leukemia in childhood. *Klin Padiatr* 1998; 210: 200-206.
 94. Filley CM. The behavioral neurology of cerebral white matter. *Neurology* 1998; 50: 1535-1540.
 95. Ciesielski KT, Lesnik PG, Sanders JA, et al. MRI morphometry of mamillary bodies, caudate nuclei, and prefrontal cortices after chemotherapy for childhood leukemia: multivariate models of early and late developing memory subsystems. *Behav Neurosci* 1999; 113: 439-450.
 96. Dietrich J, Han R, Yang Y, et al. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. *J Biol* 2006; 5: 22.1-23.
 97. Janelsins MC, Roscoe JA, Berg MJ, et al. IGF-1 partially restores chemotherapy-induced reductions in neural cell proliferation in adult C57BL/6 mice. *Cancer Invest* 2010; 28: 544-553.
 98. Ahles TA & Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. *Nat Rev Cancer* 2007; 7:192-201.
 99. Seigers R & Fardell JE. Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. *Neurosci Biobehav Rev* 2011; 35:729-741.
 100. Rubenstein CL, Varni JW and Katz ER. Cognitive functioning in long-term survivors of childhood leukemia: a prospective analysis. *J Dev Behav Pediatr* 1990; 11: 301-305.
 101. Raffa RB, Duong PV, Finney J, et al. Is chemo-fog'/'chemo-brain' caused by cancer chemotherapy? *J Clin Pharm Ther* 2006; 31: 129-138.
 102. Stock HS, Rosellini RA, Abrahamsen GC, et al. Methotrexate does not interfere with an appetitive pavlovian conditioning task in Sprague-dawley rats. *Physiol Behav* 1995; 58: 969-973.
 103. Yadin E, Bruno L, Micalizzi M, et al. An animal model to detect learning deficits following treatment of the immature brain. *Child's Brain* 1983; 10: 273-280.
 104. Yanovski JA, Packer RJ, Levine JD, et al. An animal model to detect the neuropsychological toxicity of anticancer agents. *Med Pediatr Oncol* 1989; 17: 216-221.
 105. Conklin HM, Helton S, Ashford J, et al. Predicting methylphenidate response in long-term survivors of childhood cancer: a randomized, double-blind, placebo-controlled, crossover trial. *J Pediatr Psychol* 2010; 35:144-155.
 106. Conklin HM, Khan RB, Reddick WE, et al. Acute neurocognitive response to methylphenidate among survivors of childhood cancer: a randomized, double-blind, cross-over trial. *J Pediatr Psychol* 2007; 32: 1127-1139.
 107. Waber DP, Tarbell NJ, Fair clough D, et al. Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: cranial radiation requires an accomplice. *J Clin Oncol* 1995; 13: 2490-2496.
 108. Waber DP, Tarbell NJ, Kahn CM, et al. The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia. *J Clin Oncol* 1992; 10: 810-817.
 109. Seigers R, Schagen SB, Beerling W, et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. *Behav Brain Res* 2008; 186: 168-175.
 110. Madhyastha S, Somayaji SN, Rao MS, et al. Hippocampal brain amines in methotrexate-induced learning and memory deficit. *Can J Physiol Pharmacol* 2002; 80: 1076-1084.
 111. Igarashi H, Inomata K, & Tateno A. The effect of methotrexate on the development of synapses in the neonatal rat hippocampus. *Neuropediatrics* 1989; 20:196-198.
 112. Silverstein FS & Johnston MV. A model of methotrexate encephalopathy: neurotransmitter and pathologic abnormalities. *J Child Neurol* 1986; 1:351-357.
 113. Foley JJ, Raffa RB, & Walker EA. Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory. *Psychopharmacology* 2008; 199: 527-538.
 114. Winocur G, Vardy J, Binns MA, et al. The effects of anti-cancer drugs, methotrexate and 5-fluorouracil on cognitive function in mice. *Pharmacol Biochem Behav.* 2006; 85: 66-75.
 115. Walker EA. Animal Models. In: Raffa RB and Tallarida RJ, ed. *Chemo-fog': Cancer Chemotherapy-Related Cognitive Impairment*. US: Landes Bioscience 2010.
 116. Chen D, Fu Wu C, Shi B, et al. Tamoxifen and toremifene cause impairment of learning and memory function in mice. *Pharmacol Biochem Behav* 2002; 71: 269-276.
 117. Beltagy M, Mustafa S, Umka J, et al. Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil. *Behav Brain Res* 2010; 208: 112-117.
 118. Lyons L, Beltagy M, Umka J, et al. Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by methotrexate chemotherapy. *Psychopharmacology* 2011; 215: 105-115.
 119. van Praag H, Mei Qu P, Elliott RC, et al. Unilateral hippocampal lesions in newborn and adult rats: effects on spatial memory and BDNF gene expression. *Behav Brain Res* 1998; 92: 21-30.
 120. Mullenix PJ, Kernan WJ, Schunior A, et al. Interactions of steroid, methotrexate, and radiation determine neurotoxicity in an animal model to study therapy for childhood leukemia. *Pediatr Res* 1994; 35: 171-178.
 121. Sapolsky RM. A mechanism for glucocorticoid toxicity in the hippocampus: increased neuronal vulnerability to metabolic insults. *J Neurosci* 1985; 5: 1228-1232.
 122. Li CQ, Liu D, Huang L, et al. Cytosine arabinoside treatment impairs the remote spatial memory function and induces dendritic retraction in the anterior cingulate cortex of rats. *Brain Res Bull* 2008; 77: 237-240.
 123. Borzan J, LaGraize SC, & Fuchs PN. Effect of chronic vincristine treatment on mechanical withdrawal response and pre-pulse inhibition in the rat. *Neurosci Lett* 2004; 364: 110-113.
 124. Eijkenboom M & Van Der Staay FJ. Spatial learning deficits in rats after injection of vincristine into the dorsal hippocampus. *Neuroscience* 1999; 91: 1299-1313.
 125. Liedke PE, Reolon GK, Kilpp B, et al. Systemic administration of doxorubicin impairs aversively motivated memory in rats. *Pharmacol Biochem Behav* 2009; 94: 239-243.
 126. Sieklucka-Dziuba M, Saczonek J, Dziuba J, et al. Central action of some cytostatics-methotrexate (MTX) and doxorubicin (DXR): II. The influence on the seizure activity and the learning and memory processes in mice. *Ann Univ Mariae Curie Skłodowska* 1998; 53: 81-88.
 127. Macleod JE, DeLeo JA, Hickey WF, et al. Cancer chemotherapy impairs contextual but not cue-specific fear memory. *Behav Brain Res* 2007; 181: 168-172.
 128. Konat GW, Kraszpulski M, James I, et al. Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. *Metab Brain Dis* 2008; 23: 325-333.
 129. Krull KR, Gioia G, Ness KK, et al. Reliability and validity of the childhood cancer survivor study neurocognitive questionnaire. *Cancer* 2008; 113: 2188-2197.